Sökning: WFRF:(Blimark Cecilie) >
Outcome data from >...
Outcome data from >10 000 multiple myeloma patients in the Danish and Swedish national registries
-
- Blimark, Cecilie (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för invärtesmedicin och klinisk nutrition,Institute of Medicine, Department of Internal Medicine and Clinical Nutrition
-
Vangsted, A. J. (författare)
-
Klausen, T. W. (författare)
-
visa fler...
-
Gregersen, H. (författare)
-
Szabo, A. G. (författare)
-
Hermansen, E. (författare)
-
- Walinder, G. (författare)
- Karolinska Institutet
-
Knut-Bojanowska, D. (författare)
-
- Zang, Chenyang (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för invärtesmedicin och klinisk nutrition,Institute of Medicine, Department of Internal Medicine and Clinical Nutrition
-
Turesson, I. (författare)
-
visa färre...
-
(creator_code:org_t)
- 2021-09-23
- 2022
- Engelska.
-
Ingår i: European Journal of Haematology. - : Wiley. - 0902-4441 .- 1600-0609. ; 108:2, s. 99-108
- Relaterad länk:
-
https://gup.ub.gu.se...
-
visa fler...
-
https://doi.org/10.1...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- Objective We describe real-world evidence (RWE) from the nationwide Swedish and Danish registries that provide important information on incidence and outcome in multiple myeloma (MM). Method First line treatment data on more than 10.000 MM patients from Denmark and Sweden between 2005-2018 are presented. Key results from research conducted within the Swedish and Danish myeloma registries are summarized, describing subgroups of patients with comorbidity, myeloma complications, and early relapse. Results We show that national guidelines, generated on results from randomized clinical trials (RCTs) are rapidly implemented and improve overall survival (OS). We find that both the incidence of MM and the median age at diagnosis is higher in national registries compared to results from referral centres, indicating a more complete coverage. This highlights the need of validation of prognostic scoring systems and indices in e.g., SMM and high-risk MM in a real- world-population. We show that these subgroups are unlikely to be captured in RCTs with narrow inclusion and exclusion criteria, that they have worse survival, and are in need of new treatment approaches. Conclusion National registries that include all MM patients are an important source of knowledge on epidemiology, treatment and outcome with implications for the planning of MM care. Despite the introduction of new and better treatments, rapidly implemented in our countries, our registries uncover subgroups of patients that still have inferior outcome. Our RWE can help to identify important research questions to be studied in further clinical trials also in patients currently not included in RCTs.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Hematologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Hematology (hsv//eng)
Nyckelord
- multiple myeloma
- national clinical databases
- real-world data
- stem-cell transplantation
- high-dose therapy
- high-risk
- monoclonal
- gammopathy
- clinical-course
- early relapse
- early death
- survival
- progression
- mortality
- Hematology
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Blimark, Cecilie
-
Vangsted, A. J.
-
Klausen, T. W.
-
Gregersen, H.
-
Szabo, A. G.
-
Hermansen, E.
-
visa fler...
-
Walinder, G.
-
Knut-Bojanowska, ...
-
Zang, Chenyang
-
Turesson, I.
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Hematologi
- Artiklar i publikationen
-
European Journal ...
- Av lärosätet
-
Göteborgs universitet
-
Karolinska Institutet